Accumulation of long-chain acylcarnitine and 3-hydroxy acylcarnitine molecular species in diabetic myocardium: Identification of alterations in mitochondrial fatty acid processing in diabetic myocardium by shotgun lipidomics

Xiong Su, Xianlin Han, David J. Mancuso, Dana R. Abendschein, Richard W. Gross

Research output: Contribution to journalArticle

75 Citations (Scopus)

Abstract

Diabetic cardiomyopathy is the result of maladaptive changes in energy homeostasis. However, the biochemical mechanisms underlying dysfunctional lipid metabolism in diabetic myocardium are incompletely understood. Herein, we exploit shotgun lipidomics to demonstrate a 4-fold increase in acylcarnitines in diabetic myocardium, which was reversible upon insulin treatment. Analysis of acylcarnitine molecular species in myocardium unexpectedly identified acylcarnitine molecular species containing a mass shift of 16 amu in comparison to the anticipated molecular species. Synthesis of 3-hydroxy acylcarnitine identified the natural products as the 3-hydroxylated acylcarnitines through comparisons of diagnostic fragmentation patterns of synthetic and naturally occurring constituents using tandem mass spectrometry. Diabetes induced an increase of both calcium-independent phospholipase A2 (iPLA 2) mRNA and iPLA2 activity in rat myocardium. Cardiac ischemia in myocardium genetically engineered to overexpress iPLA2 dramatically increased the amount of acylcarnitine present in myocardium. Moreover, mechanism-based inactivation of iPLA2 in either wild-type or transgenic myocardium ablated a substantial portion of the acylcarnitine increase. Collectively, these results identify discrete insulin remediable abnormalities in mitochondrial fatty acid processing in diabetic myocardium and identify iPLA2 as an important enzymatic contributor to the pool of fatty acids that can be used for acylcarnitine synthesis and energy production in myocardium.

Original languageEnglish (US)
Pages (from-to)5234-5245
Number of pages12
JournalBiochemistry
Volume44
Issue number13
DOIs
StatePublished - Apr 5 2005
Externally publishedYes

Fingerprint

Firearms
Myocardium
Fatty Acids
Processing
Calcium-Independent Phospholipase A2
Insulin
Diabetic Cardiomyopathies
acylcarnitine
Medical problems
Biological Products
Tandem Mass Spectrometry
Mass spectrometry
Lipid Metabolism
Rats
Homeostasis
Ischemia
Messenger RNA

ASJC Scopus subject areas

  • Biochemistry

Cite this

Accumulation of long-chain acylcarnitine and 3-hydroxy acylcarnitine molecular species in diabetic myocardium : Identification of alterations in mitochondrial fatty acid processing in diabetic myocardium by shotgun lipidomics. / Su, Xiong; Han, Xianlin; Mancuso, David J.; Abendschein, Dana R.; Gross, Richard W.

In: Biochemistry, Vol. 44, No. 13, 05.04.2005, p. 5234-5245.

Research output: Contribution to journalArticle

@article{4ea198b2c887492e9b4116e50b9f3aed,
title = "Accumulation of long-chain acylcarnitine and 3-hydroxy acylcarnitine molecular species in diabetic myocardium: Identification of alterations in mitochondrial fatty acid processing in diabetic myocardium by shotgun lipidomics",
abstract = "Diabetic cardiomyopathy is the result of maladaptive changes in energy homeostasis. However, the biochemical mechanisms underlying dysfunctional lipid metabolism in diabetic myocardium are incompletely understood. Herein, we exploit shotgun lipidomics to demonstrate a 4-fold increase in acylcarnitines in diabetic myocardium, which was reversible upon insulin treatment. Analysis of acylcarnitine molecular species in myocardium unexpectedly identified acylcarnitine molecular species containing a mass shift of 16 amu in comparison to the anticipated molecular species. Synthesis of 3-hydroxy acylcarnitine identified the natural products as the 3-hydroxylated acylcarnitines through comparisons of diagnostic fragmentation patterns of synthetic and naturally occurring constituents using tandem mass spectrometry. Diabetes induced an increase of both calcium-independent phospholipase A2 (iPLA 2) mRNA and iPLA2 activity in rat myocardium. Cardiac ischemia in myocardium genetically engineered to overexpress iPLA2 dramatically increased the amount of acylcarnitine present in myocardium. Moreover, mechanism-based inactivation of iPLA2 in either wild-type or transgenic myocardium ablated a substantial portion of the acylcarnitine increase. Collectively, these results identify discrete insulin remediable abnormalities in mitochondrial fatty acid processing in diabetic myocardium and identify iPLA2 as an important enzymatic contributor to the pool of fatty acids that can be used for acylcarnitine synthesis and energy production in myocardium.",
author = "Xiong Su and Xianlin Han and Mancuso, {David J.} and Abendschein, {Dana R.} and Gross, {Richard W.}",
year = "2005",
month = "4",
day = "5",
doi = "10.1021/bi047773a",
language = "English (US)",
volume = "44",
pages = "5234--5245",
journal = "Biochemistry",
issn = "0006-2960",
publisher = "American Chemical Society",
number = "13",

}

TY - JOUR

T1 - Accumulation of long-chain acylcarnitine and 3-hydroxy acylcarnitine molecular species in diabetic myocardium

T2 - Identification of alterations in mitochondrial fatty acid processing in diabetic myocardium by shotgun lipidomics

AU - Su, Xiong

AU - Han, Xianlin

AU - Mancuso, David J.

AU - Abendschein, Dana R.

AU - Gross, Richard W.

PY - 2005/4/5

Y1 - 2005/4/5

N2 - Diabetic cardiomyopathy is the result of maladaptive changes in energy homeostasis. However, the biochemical mechanisms underlying dysfunctional lipid metabolism in diabetic myocardium are incompletely understood. Herein, we exploit shotgun lipidomics to demonstrate a 4-fold increase in acylcarnitines in diabetic myocardium, which was reversible upon insulin treatment. Analysis of acylcarnitine molecular species in myocardium unexpectedly identified acylcarnitine molecular species containing a mass shift of 16 amu in comparison to the anticipated molecular species. Synthesis of 3-hydroxy acylcarnitine identified the natural products as the 3-hydroxylated acylcarnitines through comparisons of diagnostic fragmentation patterns of synthetic and naturally occurring constituents using tandem mass spectrometry. Diabetes induced an increase of both calcium-independent phospholipase A2 (iPLA 2) mRNA and iPLA2 activity in rat myocardium. Cardiac ischemia in myocardium genetically engineered to overexpress iPLA2 dramatically increased the amount of acylcarnitine present in myocardium. Moreover, mechanism-based inactivation of iPLA2 in either wild-type or transgenic myocardium ablated a substantial portion of the acylcarnitine increase. Collectively, these results identify discrete insulin remediable abnormalities in mitochondrial fatty acid processing in diabetic myocardium and identify iPLA2 as an important enzymatic contributor to the pool of fatty acids that can be used for acylcarnitine synthesis and energy production in myocardium.

AB - Diabetic cardiomyopathy is the result of maladaptive changes in energy homeostasis. However, the biochemical mechanisms underlying dysfunctional lipid metabolism in diabetic myocardium are incompletely understood. Herein, we exploit shotgun lipidomics to demonstrate a 4-fold increase in acylcarnitines in diabetic myocardium, which was reversible upon insulin treatment. Analysis of acylcarnitine molecular species in myocardium unexpectedly identified acylcarnitine molecular species containing a mass shift of 16 amu in comparison to the anticipated molecular species. Synthesis of 3-hydroxy acylcarnitine identified the natural products as the 3-hydroxylated acylcarnitines through comparisons of diagnostic fragmentation patterns of synthetic and naturally occurring constituents using tandem mass spectrometry. Diabetes induced an increase of both calcium-independent phospholipase A2 (iPLA 2) mRNA and iPLA2 activity in rat myocardium. Cardiac ischemia in myocardium genetically engineered to overexpress iPLA2 dramatically increased the amount of acylcarnitine present in myocardium. Moreover, mechanism-based inactivation of iPLA2 in either wild-type or transgenic myocardium ablated a substantial portion of the acylcarnitine increase. Collectively, these results identify discrete insulin remediable abnormalities in mitochondrial fatty acid processing in diabetic myocardium and identify iPLA2 as an important enzymatic contributor to the pool of fatty acids that can be used for acylcarnitine synthesis and energy production in myocardium.

UR - http://www.scopus.com/inward/record.url?scp=16344395330&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=16344395330&partnerID=8YFLogxK

U2 - 10.1021/bi047773a

DO - 10.1021/bi047773a

M3 - Article

C2 - 15794660

AN - SCOPUS:16344395330

VL - 44

SP - 5234

EP - 5245

JO - Biochemistry

JF - Biochemistry

SN - 0006-2960

IS - 13

ER -